LitCovid-sentences  

PMC:7335494 / 69241-76036 JSONTXT 12 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T396 0-232 Sentence denotes In patients with impaired glucose metabolism and T2DM in almost all studies, none of the combined EPA and DHA doses had any effect on IL-6, IL-1β, CRP, VCAM, and sICAM (Clark et al., 2016; Mocking et al., 2012; Sawada et al., 2016).
T397 233-406 Sentence denotes Further, no effects on glycated haemoglobin (HbA1c) (Sawada et al., 2016; Wong et al., 2010), insulin (Clark et al., 2016) or lipid profile (Veleba et al., 2015) were found.
T398 407-581 Sentence denotes Only Veleba et al. (2015), observed that HbA1c decreased significantly, and fasting blood glucose increased after n-3 PUFAs treatment for 24 weeks, but no other key findings.
T399 582-755 Sentence denotes An overview of the most recent human studies where the inflammatory biomarkers as a result of PUFAs treatments, were assessed as the main outcome, is summarized in Table 6 .
T400 756-798 Sentence denotes Table 6 Clinical effects induced by PUFAs.
T401 799-882 Sentence denotes Intervention (n) Main anti-inflammatory findings Other relevant findings References
T402 883-899 Sentence denotes Healthy subjects
T403 900-971 Sentence denotes 4-month intervention:➢ 1.5 g fish oil (1042.5 mg EPA and 174 DHA daily)
T404 972-1023 Sentence denotes ➢ 2.5 g fish oil (2085 mg EPA and 348 mg DHA daily)
T405 1024-1168 Sentence denotes ➢ placebo 138 ↓TNF-α and ↓ IL-6 for both low and high dose groups ↓ n-6:n-3 ratio for both low and high dose groups Kiecolt-Glaser et al. (2012)
T406 1169-1205 Sentence denotes 6-week intervention:➢ 600 mg EPA/day
T407 1206-1223 Sentence denotes ➢ 1800 mg EPA/day
T408 1224-1240 Sentence denotes ➢ 600 mg DHA/day
T409 1241-1411 Sentence denotes ➢ placebo 121 No effect on hsCRP, TNF-α, IL-6, VCAM-1, ICAM-1 and fibrinogen Only High dose EPA ↓ Lp-PLA2;DHA: ↓ TG; ↑ LDLNo effect of low dose EPA Asztalos et al. (2016)
T410 1412-1533 Sentence denotes 18-week intervention:1000 mg EPA + 400 mg DHA/day vs. placebo 261 No effect on serum CRP and IL-6 – Muldoon et al. (2016)
T411 1534-1577 Sentence denotes 5-month intervention:➢ 300 mg EPA + DHA/day
T412 1578-1600 Sentence denotes ➢ 600 mg EPA + DHA/day
T413 1601-1623 Sentence denotes ➢ 900 mg EPA + DHA/day
T414 1624-1647 Sentence denotes ➢ 1800 mg EPA + DHA/day
T415 1648-1825 Sentence denotes ➢ placebo 125 No significant effect on IL-6 or CPR;Marginal effect on TNF-α observed at the highest dose (1800 mg) Higher RBC DHA was associated with lower TNF-α concentrations.
T416 1826-1845 Sentence denotes Flock et al. (2014)
T417 1846-1944 Sentence denotes 8-week intervention:2500 mg EPA + DHA/day vs. placebo 35 ↓IL-6, IL-1β and TNFα – Tan et al. (2018)
T418 1945-1959 Sentence denotes Obese patients
T419 1960-2012 Sentence denotes 2-month intervention:➢ 460 mg EPA and 380 mg DHA/day
T420 2013-2176 Sentence denotes ➢ control (butter fat) 55 ↓IL-6↓ inflammatory gene expression in adipose tissue↑release of anti-inflammatory eicosanoids in adipose tissue ↓TG Itariu et al. (2012)
T421 2177-2198 Sentence denotes 3-month intervention:
T422 2199-2363 Sentence denotes 360 mg EPA and 1290 mg DHA/day vs. placebo 59 ↓ VCAM-1; ↓ PECAM-1; ↓ hsCRP No effect on IL-6 ↓ TG; ↓insulin.No effect on TC, HDL, LDL, NEFA, FBG Polus et al. (2016)
T423 2364-2402 Sentence denotes 10-week intervention:➢ 2700 mg EPA/day
T424 2403-2420 Sentence denotes ➢ 2700 mg DHA/day
T425 2421-2611 Sentence denotes ➢ placebo 154 ↓ IL-18 and ↑ adiponectin (DHA > EPA)No difference between EPA and DHA regarding effect on CRP, IL-6, TNFα ↓ TG; ↑ HDL (DHA > EPA)↑ LDL by DHA only in men Allaire et al. (2016)
T426 2612-2650 Sentence denotes 10-week intervention:➢ 2700 mg EPA/day
T427 2651-2668 Sentence denotes ➢ 2700 mg DHA/day
T428 2669-2827 Sentence denotes ➢ control (corn oil) 154 EPA: ↑TRAF3 and PPARα expressionDHA: ↑ PPARα and TNFα expression both ↓CD14 expression No significant difference between EPA and DHA.
T429 2828-2846 Sentence denotes Vors et al. (2017)
T430 2847-2896 Sentence denotes 12-week intervention:➢ LSM + 600 mg EPA + DHA/day
T431 2897-2902 Sentence denotes ➢ LSM
T432 2903-3077 Sentence denotes ➢ placebo 29 LSM & n-3 PUFA ↑ adiponectin in comparison to LSMNo effect on IL6 No effect on leptin, LIF, follistatin, BDNF, and fasting triacylglycerol Sedláček et al. (2018)
T433 3078-3121 Sentence denotes Hypertensive and/or diabetic obese patients
T434 3122-3221 Sentence denotes 8-week intervention:300 mg EPA + 200 mg DHA/day vs. control 64 ↓CRP ↓ FBG; ↓TG Ellulu et al. (2016)
T435 3222-3258 Sentence denotes Impaired glucose metabolism patients
T436 3259-3419 Sentence denotes 6-month intervention:1800 mg EPA/day vs. placebo 107 ↓ CRP but similar effects in placebo ↑ HDL and ↓fasting TG; No effect on HbA1c and FBG Sawada et al. (2016)
T437 3420-3566 Sentence denotes 9-month intervention:2388 mg EPA +1530 mg DHA/day vs placebo 36 No effect in IL-1B, IL-6, hsCRP, ICAM and VCAM No effect on FBG, insulin, HOMA-IR.
T438 3567-3586 Sentence denotes Clark et al. (2016)
T439 3587-3611 Sentence denotes Type 2 diabetes mellitus
T440 3612-3633 Sentence denotes 12-week intervention:
T441 3634-3762 Sentence denotes 4000 mg (42% EPA + 25%DHA)/day vs. placebo 91 No significant effect on CPR ↓ TG; No effect on LDL, HDL, HbA1c Wong et al. (2010)
T442 3763-3784 Sentence denotes 12-week intervention:
T443 3785-3898 Sentence denotes 900 mg EPA/day vs. placebo 24 No effect on CRP, IL-6 and TNFα ↑ HDL and ↑ total cholesterol Mocking et al. (2012)
T444 3899-3919 Sentence denotes 8-week intervention:
T445 3920-4024 Sentence denotes 2700 mg EPA + DHA/day 84 ↓ IL-2 and ↓ TNFαNo effect on CRP None tested Malekshahi Moghadam et al. (2012)
T446 4025-4064 Sentence denotes 12-weeks intervention:➢ 1000 mg EPA/day
T447 4065-4082 Sentence denotes ➢ 1000 mg DHA/day
T448 4083-4197 Sentence denotes ➢ placebo 60 No effect on serum CRP and MDA No effect on body weight, BMI or fat mass Azizi-Soleiman et al. (2013)
T449 4198-4263 Sentence denotes 24-week intervention:➢ 2800 mg EPA + DHA + 15 mg pioglitazone/day
T450 4264-4297 Sentence denotes ➢ 2800 mg EPA + DHA + placebo/day
T451 4298-4321 Sentence denotes ➢ 5 mg pioglitazone/day
T452 4322-4459 Sentence denotes ➢ placebo 60 No effect on SOD, TBARS, GSSG/GSH ↑ HbA1c; ↑FBGNo effect on TG, TC, HDL, LDL, NEFA, Leptin, Adiponectin Veleba et al. (2015)
T453 4460-4481 Sentence denotes 3-month intervention:
T454 4482-4662 Sentence denotes 1000 mg EPA + 1000 mg DHA/day vs. placebo 74 No effect on hsCRP, IL-6, TNF-α, ICAM-1, VCAM-1 No effect on insulin, HbA1c, adiponectin, leptin, and lipid levels Poreba et al. (2017)
T455 4663-4681 Sentence denotes Metabolic syndrome
T456 4682-4757 Sentence denotes 90-day intervention:➢ 1800 mg EPA+ 1200 mg DHA + 10 mL extra virgin oil/day
T457 4758-4799 Sentence denotes ➢ 1800 mg EPA + 1200 mg DHA + placebo/day
T458 4800-4828 Sentence denotes ➢ 10 mL extra virgin oil/day
T459 4829-4936 Sentence denotes ➢ placebo 102 No effect on CPR No effect on TG, TC, HDL, LDL, FBG, insulin, HOMA-IR Venturini et al. (2015)
T460 4937-4963 Sentence denotes Inflammatory bowel disease
T461 4964-4984 Sentence denotes 8-week intervention:
T462 4985-5209 Sentence denotes 3400–3600 mg n-3 PUFA (as salmon)/day 12 ↓ CPR, ↑ anti-inflammatory fatty acid indexNo effect TNF- α, MDA ↑ n-3 PUFAs,↑ n-3/n-6 ratio in plasma and rectal biopsies; No effect on the fecal calprotectine Grimstad et al. (2011)
T463 5210-5230 Sentence denotes 90-day intervention:
T464 5231-5382 Sentence denotes 2000 mg EPA/day 20 ↑ IL-10 expression; HES1, SOCS3, and KLF4 ↓ fecal calprotectinePartially redressed microbiota composition Prossomariti et al. (2017)
T465 5383-5404 Sentence denotes 6-month intervention:
T466 5405-5495 Sentence denotes 1000 mg EPA/day vs.placebo 60 No effect on CPR ↓ fecal calprotectine Scaioli et al. (2018)
T467 5496-6795 Sentence denotes EPA – Eicosapentaenoic Acid; DHA – Docosahexaenoic Acid; PG – Prostaglandins; LTB – Leukotriene; TNF-α – Tumour Necrosis Factor alpha; IL – Interleukin; CRP – C-Reactive Protein; ICAM – Intercellular Adhesion Molecule; VCAM – Vascular Cell Adhesion molecule; hsCRP – high sensitive C reactive protein; IL1RN – interleukin-1 receptor antagonist protein; LSM – lifestyle modification; NF-κB – nuclear factor-kappa B); PPAR – peroxisome proliferator-activated receptor; TRAF3 – TNF Receptor Associated Factor 3; Lp-PLA2 – lipoprotein-associated phospholipase A2; PECAM – platelet and endothelial cell adhesion molecule; COX – cyclooxygenase; LOX – lypoooxigenase; TBARS –thiobarbituric acid substances; SOD – superoxide dismutase; GSH – glutathione peroxidase; MDA – malonyldialdehyde; HOMA-IR – homeostasis model assessment of insulin resistance index; HES1 – transcription factor HES1; SOCCS3 – suppressor of cytokine signaling 3; KLF4 – Kruppel-like factor 4; HbA1c – Glycated haemoglobin; RBC – red blood cell; BDNF – Brain-derived neurotrophic factor; CD14 – cluster of differentiation 14; NEFA – Non-esterified fatty acids; TC – total cholesterol; TG – Triglycerides; LDL – low-density lipoproteins; HDL – high-density lipoproteins; FBG – fasting blood glucose; LIF – leukocyte inhibitory factor.